Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a radiopharmaceutical injection kit for intravenous use. It is employed in cardiac imaging to evaluate myocardial perfusion and viability, primarily in patients being assessed for coronary artery disease.

GNH USA supplies Myoview as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, clinics and diagnostic centres worldwide. The product complies with EU regulatory standards and is distributed under strict quality controls.

Myoview (tetrofosmin) is used in cardiac imaging to assess myocardial perfusion and viability. - Coronary artery disease: detection of perfusion defects during stress and rest SPECT imaging. - Myocardial viability assessment: evaluation of viable myocardium after infarction to guide revascularization decisions. - Ischemic heart disease: identification of regional blood flow abnormalities for risk stratification.

Adverse reactions to Myoview are generally related to the radiopharmaceutical nature of the product and its intravenous administration.

Common Side Effects: - Injection site pain or erythema. - Nausea or mild vomiting. - Flushing or warmth sensation. - Headache or dizziness.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Significant hypotension or cardiovascular collapse. - Cardiac arrhythmias. - Radiation‑induced skin injury at the injection site.

Precautions should be observed when using Myoview to minimize risks and ensure accurate imaging results. - Pregnancy: avoid use unless clearly needed, as fetal radiation exposure is unknown. - Breastfeeding: discontinue breastfeeding or discontinue the drug, due to potential radiation transfer. - Renal impairment: assess renal function, as reduced clearance may affect radiation dose. - Concomitant stress agents: coordinate with pharmacologic stress agents (e.g., dipyridamole) to avoid adverse hemodynamic effects. - Thyroid blocking agents: avoid recent iodine or perchlorate administration that may alter tracer distribution. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other substances that affect tracer distribution or cardiovascular response.

Major Interactions (Avoid): - Iodine or perchlorate compounds: may interfere with technetium uptake and reduce image quality. - Beta‑blockers: can blunt heart rate response during pharmacologic stress, affecting interpretation. - Calcium channel blockers: may alter myocardial blood flow and affect tracer distribution.

Moderate Interactions (Monitor Closely): - Caffeine or theophylline: can antagonize vasodilator stress agents used with Myoview. - Other radiopharmaceuticals: cumulative radiation dose should be considered. - Vasodilator agents (e.g., dipyridamole, adenosine): require careful dosing and monitoring to prevent excessive hypotension.